Latest News
NOW Money has closed its bridge funding round with a total of USD1.46 million in commitments.
In addition to a recent US Venture Capital investment, this funding round includes USD700,000 from Dubai-based Venture Capital firm, Myrisoph Capital. Other contributions have come from private investors and MENA-based women’s investor network WAIN.
Myrisoph Capital focuses on investments into SMEs that want expert advice and mentorship to take their business to the next level. It invests specifically within the team’s core skill-set and expertise, and in territories they know well, ensuring they can provide the best support possible.
WAIN is the
OrbiMed, an investment firm focused on the healthcare sector, has closed its third Asia-focused private equity fund, OrbiMed Asia Partners III, LP, with approximately USD551 million in capital commitments.
Consistent with its predecessor funds, Asia Partners III will invest broadly across the Asian healthcare industry, with a focus on growth stage product- and services-oriented companies in China and India. The Fund will target investments from USD10 million to USD75 million per company across 15 to 20 opportunities. Where appropriate, Asia Partners III may co-invest with OrbiMed’s global team, enabling substantially larger investments and leveraging the full financial and strategic resources
European private equity firm Silverfleet Capital has promoted Mark Piasecki, Klaus Maurer and Jean Châtillon to partners in the firm.
Piasecki is based in London and joined Silverfleet more than ten years ago. During this time, he has been responsible for making investments across most of Silverfleet’s target sectors including Business & Financial Services and Retail, Leisure & Consumer Products. Piasecki will continue his role as Head of the Financial Services sector and will maintain his focus on investment activities across the UK & Ireland.
Maurer has been with Silverfleet for eight years and is based in the Firm’s
StageOne Ventures, an early stage venture capital firm focusing on Israel-related technology startups, has closed ts third venture capital fund, with USD110 million in committed capital.
Led by Yuval Cohen, Yoav Samet, and Tal Slobodkin, with presence both in Tel Aviv and in Palo Alto, StageOne Ventures helps entrepreneurs traverse the Israel-Silicon Valley axis and build global businesses.
Stage One Venture Capital Fund III (StageOne III), the firm’s largest fund to date, closed at USD110 million after an oversubscribed fundraising process in summer 2017. StageOne III is backed primarily by StageOne’s existing LPs, with the addition of several prominent
Albion Capital is seeking to raise up to GBP38 million through top up offers for its six venture capital trusts (VCTs).
The fundraising targets GBP8 million for Kings Arms Yard VCT and GBP6 million across each of Albion’s other VCTs. Investments spread across all six portfolios will receive a monthly dividend with a yield of approximately 5.6 per cent, or 8.0 per cent after tax relief, a potentially attractive income source in the current low interest rate environment.
Investors who apply before 2pm on 31 October 2017 for the first GBP10 million of shares will be entitled to an “early
Thierry de Vergnes has joined Amundi as Head of Debt Fund Management within its dedicated platform for real and alternative assets.
De Vergnes (pictured), previously worked at Lyxor where he created the debt fund management business, having spent nine years at Société Générale.
From 1985 until 2003, he worked at Indosuez Bank first in Paris, then London and finally he joined the New York office where he was Group Head of Indosuez Capital, the acquisition finance department of the bank in the US.
De Vergnes holds an MBA from the Institut Français du Pétrole and a Degree in
By Fiona Le Poidevin (pictured), CEO, The International Stock Exchange Group – There are a number of advantages of listing on TISE, including the ability to demonstrate additional substance within and create value for investment structures, says Fiona Le Poidevin, CEO, The International Stock Exchange Group.
Asset management groups are still coming to terms with the fact that international developments such as the EU’s Alternative Investment Fund Managers Directive (AIFMD) and the OECD’s Base Erosion and Profit Shifting (BEPS) initiative have placed increased focus on the substance of investment structures.
However, there are a number of advantages of listing on TISE,
Withinlink CEO Bessie Lee (pictured), has announced the launch of the firm’s second venture capital fund this year – a new USD30 million fund that is aiming to bring startups to China.
“As our world globalises and China gentrifies, there has never been a better time to bridge the gap between Silicon Valley innovation and the China market,” says Lee. “Withinlink Venture Fund 2.0 will invest in US-based companies with products and services poised for takeoff in China.”
The new Withinlink fund, which follows a RMB fund which closed this past March, will target mid- to late-stage US media
Private equity firm Activa Capital’s portfolio company Mecadaq, a provider of high precision manufacturing for the aerospace industry, has acquired Armoa, a specialist in high precision machining.
The acquisition takes place 18 months after the creation by Activa Capital of a consolidation platform in aerospace subcontracting. This is the second significant build-up for Mecadaq, which already generates revenues of EUR32 million in aeronautic subcontracting, primarily in the area of machining of aero structure parts for civil aircraft. Financed with bank debt and additional capital provided by Activa Capital and Mecadaq’s management, the acquisition will increase the group’s revenues to over
AMAL Therapeutics (AMAL), a Swiss biotech developing peptide-based therapeutic cancer vaccines, has completed the first tranche of its Series B financing round, raising EUR8 million (CHF8.8 million).
The Company will use the funds to progress its lead vaccine (ATP128) towards clinical studies and proof-of-concept in colorectal cancer. It will also further develop its proprietary therapeutic tumour vaccination technology platform called KISIMA.
Boehringer Ingelheim Venture Fund (BIVF), BioMedPartners and Helsinn Investment Fund are cornerstone investors, with VI Partners, High-Tech Gründerfonds and Schroder Adveq also participating.
AMAL is Schroder Adveq’s first investment in Life Sciences in Switzerland. It is also
Special Reports
Featured
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
